UCB S.A.

UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
  • TickerUCB
  • ISINBE0003739530
  • ExchangeEuronext Brussels
  • SectorPharmaceuticals & Biotechnology
  • CountryBelgium
David Vagman ... (+3)
  • David Vagman
  • CFA
  • Maxime Stranart
UCB UCB S.A. (Health Care)

UCB/Preview: Strong 1H21 ahead, 4Q21 trials are key/BUY

We reiterate our BUY on UCB and increase our target price from €120 to €125 following the re-rating of our sample of EU Pharma Midcaps, which are now trading at 21.9x Norm. PER 2021F, vs 14.7x for UCB, despite double-digit core EPS CAGR over 2020-23F and significantly higher R&D investments. Our Embedded Value remains unchanged at €129 per share, as we remain convinced by Bimzelx game changer potential. UCB will report its 1H21 results on 29 July, and we expect strong core EPS growth at +9.7% thanks to the continued growth of blockbusters Cimzia and Vimpat, whilst Evenity's sales growth in the...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Sebastien Malafosse
UCB UCB S.A. (Health Care)

UCB : Bimekizumab on the right track

>Bimekizumab: positive recommendation from CHMP in psoriasis - UCB’s share price gained +3% last Friday (after trading was momentarily suspended) following the positive recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for bimekizumab in the treatment of moderate to severe plaque psoriasis. We are not surprised by this verdict which is more a confirmation of our opinion on its clinical development. To recap, the phase III data (BE SUR...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Sebastien Malafosse
UCB UCB S.A. (Health Care)

UCB : Bimekizumab sur de bons rails

>Bimekizumab : CHMP positif dans le psoriasis - Le cours d’UCB progressait de +3% vendredi dernier (après une suspension momentanée du cours) à la suite d’une recommandation positive du Comité des médicaments à usage humain (CHMP) de l’EMA pour bimekizumab dans le traitement du psoriasis en plaques modéré à sévère. Nous ne voyons pas ce verdict comme une surprise mais plutôt comme la confirmation de notre opinion sur son développement clinique. Pour rappel, les résul...

Jean-Jacques Le Fur
  • Jean-Jacques Le Fur
UCB UCB S.A. (Health Care)

UCB: The right time to look again at UCB | BUY | EUR133(+59%)

UCB - BUY | EUR133(+59%) The right time to look again at UCB A share price under pressure without good reasons 2022, a transition year Before a very solid recovery starting in 2023. Buy rating reiterated

UCB UCB S.A. (Health Care)

Ucb SA: 1 director

A director at Ucb SA bought 251 shares at 78.408EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members ...

David Vagman ... (+3)
  • David Vagman
  • CFA
  • Maxime Stranart
UCB UCB S.A. (Health Care)

UCB/Preview: Strong 1H21 ahead, 4Q21 trials are key/BUY

We reiterate our BUY on UCB and increase our target price from €120 to €125 following the re-rating of our sample of EU Pharma Midcaps, which are now trading at 21.9x Norm. PER 2021F, vs 14.7x for UCB, despite double-digit core EPS CAGR over 2020-23F and significantly higher R&D investments. Our Embedded Value remains unchanged at €129 per share, as we remain convinced by Bimzelx game changer potential. UCB will report its 1H21 results on 29 July, and we expect strong core EPS growth at +9.7% thanks to the continued growth of blockbusters Cimzia and Vimpat, whilst Evenity's sales growth in the...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Sebastien Malafosse
UCB UCB S.A. (Health Care)

UCB : Bimekizumab on the right track

>Bimekizumab: positive recommendation from CHMP in psoriasis - UCB’s share price gained +3% last Friday (after trading was momentarily suspended) following the positive recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for bimekizumab in the treatment of moderate to severe plaque psoriasis. We are not surprised by this verdict which is more a confirmation of our opinion on its clinical development. To recap, the phase III data (BE SUR...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Sebastien Malafosse
UCB UCB S.A. (Health Care)

UCB : Bimekizumab sur de bons rails

>Bimekizumab : CHMP positif dans le psoriasis - Le cours d’UCB progressait de +3% vendredi dernier (après une suspension momentanée du cours) à la suite d’une recommandation positive du Comité des médicaments à usage humain (CHMP) de l’EMA pour bimekizumab dans le traitement du psoriasis en plaques modéré à sévère. Nous ne voyons pas ce verdict comme une surprise mais plutôt comme la confirmation de notre opinion sur son développement clinique. Pour rappel, les résul...

Jean-Jacques Le Fur
  • Jean-Jacques Le Fur
UCB UCB S.A. (Health Care)

UCB: The right time to look again at UCB | BUY | EUR133(+59%)

UCB - BUY | EUR133(+59%) The right time to look again at UCB A share price under pressure without good reasons 2022, a transition year Before a very solid recovery starting in 2023. Buy rating reiterated

UCB UCB S.A. (Health Care)

Ucb SA: 1 director

A director at Ucb SA bought 251 shares at 78.408EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members ...

David Vagman ... (+3)
  • David Vagman
  • CFA
  • Maxime Stranart
UCB UCB S.A. (Health Care)

UCB/Preview: Strong 1H21 ahead, 4Q21 trials are key/BUY

We reiterate our BUY on UCB and increase our target price from €120 to €125 following the re-rating of our sample of EU Pharma Midcaps, which are now trading at 21.9x Norm. PER 2021F, vs 14.7x for UCB, despite double-digit core EPS CAGR over 2020-23F and significantly higher R&D investments. Our Embedded Value remains unchanged at €129 per share, as we remain convinced by Bimzelx game changer potential. UCB will report its 1H21 results on 29 July, and we expect strong core EPS growth at +9.7% thanks to the continued growth of blockbusters Cimzia and Vimpat, whilst Evenity's sales growth in the...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Sebastien Malafosse
UCB UCB S.A. (Health Care)

UCB : Bimekizumab on the right track

>Bimekizumab: positive recommendation from CHMP in psoriasis - UCB’s share price gained +3% last Friday (after trading was momentarily suspended) following the positive recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for bimekizumab in the treatment of moderate to severe plaque psoriasis. We are not surprised by this verdict which is more a confirmation of our opinion on its clinical development. To recap, the phase III data (BE SUR...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Sebastien Malafosse
UCB UCB S.A. (Health Care)

UCB : Bimekizumab sur de bons rails

>Bimekizumab : CHMP positif dans le psoriasis - Le cours d’UCB progressait de +3% vendredi dernier (après une suspension momentanée du cours) à la suite d’une recommandation positive du Comité des médicaments à usage humain (CHMP) de l’EMA pour bimekizumab dans le traitement du psoriasis en plaques modéré à sévère. Nous ne voyons pas ce verdict comme une surprise mais plutôt comme la confirmation de notre opinion sur son développement clinique. Pour rappel, les résul...

Jean-Jacques Le Fur
  • Jean-Jacques Le Fur
UCB UCB S.A. (Health Care)

UCB: The right time to look again at UCB | BUY | EUR133(+59%)

UCB - BUY | EUR133(+59%) The right time to look again at UCB A share price under pressure without good reasons 2022, a transition year Before a very solid recovery starting in 2023. Buy rating reiterated

UCB UCB S.A. (Health Care)

Ucb SA: 1 director

A director at Ucb SA bought 251 shares at 78.408EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members ...

David Vagman ... (+3)
  • David Vagman
  • CFA
  • Maxime Stranart
UCB UCB S.A. (Health Care)

UCB/Preview: Strong 1H21 ahead, 4Q21 trials are key/BUY

We reiterate our BUY on UCB and increase our target price from €120 to €125 following the re-rating of our sample of EU Pharma Midcaps, which are now trading at 21.9x Norm. PER 2021F, vs 14.7x for UCB, despite double-digit core EPS CAGR over 2020-23F and significantly higher R&D investments. Our Embedded Value remains unchanged at €129 per share, as we remain convinced by Bimzelx game changer potential. UCB will report its 1H21 results on 29 July, and we expect strong core EPS growth at +9.7% thanks to the continued growth of blockbusters Cimzia and Vimpat, whilst Evenity's sales growth in the...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Sebastien Malafosse
UCB UCB S.A. (Health Care)

UCB : Bimekizumab on the right track

>Bimekizumab: positive recommendation from CHMP in psoriasis - UCB’s share price gained +3% last Friday (after trading was momentarily suspended) following the positive recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for bimekizumab in the treatment of moderate to severe plaque psoriasis. We are not surprised by this verdict which is more a confirmation of our opinion on its clinical development. To recap, the phase III data (BE SUR...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Sebastien Malafosse
UCB UCB S.A. (Health Care)

UCB : Bimekizumab sur de bons rails

>Bimekizumab : CHMP positif dans le psoriasis - Le cours d’UCB progressait de +3% vendredi dernier (après une suspension momentanée du cours) à la suite d’une recommandation positive du Comité des médicaments à usage humain (CHMP) de l’EMA pour bimekizumab dans le traitement du psoriasis en plaques modéré à sévère. Nous ne voyons pas ce verdict comme une surprise mais plutôt comme la confirmation de notre opinion sur son développement clinique. Pour rappel, les résul...

Jean-Jacques Le Fur
  • Jean-Jacques Le Fur
UCB UCB S.A. (Health Care)

UCB: The right time to look again at UCB | BUY | EUR133(+59%)

UCB - BUY | EUR133(+59%) The right time to look again at UCB A share price under pressure without good reasons 2022, a transition year Before a very solid recovery starting in 2023. Buy rating reiterated

UCB UCB S.A. (Health Care)

Ucb SA: 1 director

A director at Ucb SA bought 251 shares at 78.408EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members ...

David Vagman ... (+3)
  • David Vagman
  • CFA
  • Maxime Stranart
UCB UCB S.A. (Health Care)

UCB/Preview: Strong 1H21 ahead, 4Q21 trials are key/BUY

We reiterate our BUY on UCB and increase our target price from €120 to €125 following the re-rating of our sample of EU Pharma Midcaps, which are now trading at 21.9x Norm. PER 2021F, vs 14.7x for UCB, despite double-digit core EPS CAGR over 2020-23F and significantly higher R&D investments. Our Embedded Value remains unchanged at €129 per share, as we remain convinced by Bimzelx game changer potential. UCB will report its 1H21 results on 29 July, and we expect strong core EPS growth at +9.7% thanks to the continued growth of blockbusters Cimzia and Vimpat, whilst Evenity's sales growth in the...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Sebastien Malafosse
UCB UCB S.A. (Health Care)

UCB : Bimekizumab on the right track

>Bimekizumab: positive recommendation from CHMP in psoriasis - UCB’s share price gained +3% last Friday (after trading was momentarily suspended) following the positive recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for bimekizumab in the treatment of moderate to severe plaque psoriasis. We are not surprised by this verdict which is more a confirmation of our opinion on its clinical development. To recap, the phase III data (BE SUR...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Sebastien Malafosse
UCB UCB S.A. (Health Care)

UCB : Bimekizumab sur de bons rails

>Bimekizumab : CHMP positif dans le psoriasis - Le cours d’UCB progressait de +3% vendredi dernier (après une suspension momentanée du cours) à la suite d’une recommandation positive du Comité des médicaments à usage humain (CHMP) de l’EMA pour bimekizumab dans le traitement du psoriasis en plaques modéré à sévère. Nous ne voyons pas ce verdict comme une surprise mais plutôt comme la confirmation de notre opinion sur son développement clinique. Pour rappel, les résul...

Jean-Jacques Le Fur
  • Jean-Jacques Le Fur
UCB UCB S.A. (Health Care)

UCB: The right time to look again at UCB | BUY | EUR133(+59%)

UCB - BUY | EUR133(+59%) The right time to look again at UCB A share price under pressure without good reasons 2022, a transition year Before a very solid recovery starting in 2023. Buy rating reiterated

UCB UCB S.A. (Health Care)

Ucb SA: 1 director

A director at Ucb SA bought 251 shares at 78.408EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members ...

David Vagman ... (+3)
  • David Vagman
  • CFA
  • Maxime Stranart
UCB UCB S.A. (Health Care)

UCB/Preview: Strong 1H21 ahead, 4Q21 trials are key/BUY

We reiterate our BUY on UCB and increase our target price from €120 to €125 following the re-rating of our sample of EU Pharma Midcaps, which are now trading at 21.9x Norm. PER 2021F, vs 14.7x for UCB, despite double-digit core EPS CAGR over 2020-23F and significantly higher R&D investments. Our Embedded Value remains unchanged at €129 per share, as we remain convinced by Bimzelx game changer potential. UCB will report its 1H21 results on 29 July, and we expect strong core EPS growth at +9.7% thanks to the continued growth of blockbusters Cimzia and Vimpat, whilst Evenity's sales growth in the...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Sebastien Malafosse
UCB UCB S.A. (Health Care)

UCB : Bimekizumab on the right track

>Bimekizumab: positive recommendation from CHMP in psoriasis - UCB’s share price gained +3% last Friday (after trading was momentarily suspended) following the positive recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for bimekizumab in the treatment of moderate to severe plaque psoriasis. We are not surprised by this verdict which is more a confirmation of our opinion on its clinical development. To recap, the phase III data (BE SUR...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Sebastien Malafosse
UCB UCB S.A. (Health Care)

UCB : Bimekizumab sur de bons rails

>Bimekizumab : CHMP positif dans le psoriasis - Le cours d’UCB progressait de +3% vendredi dernier (après une suspension momentanée du cours) à la suite d’une recommandation positive du Comité des médicaments à usage humain (CHMP) de l’EMA pour bimekizumab dans le traitement du psoriasis en plaques modéré à sévère. Nous ne voyons pas ce verdict comme une surprise mais plutôt comme la confirmation de notre opinion sur son développement clinique. Pour rappel, les résul...

Jean-Jacques Le Fur
  • Jean-Jacques Le Fur
UCB UCB S.A. (Health Care)

UCB: The right time to look again at UCB | BUY | EUR133(+59%)

UCB - BUY | EUR133(+59%) The right time to look again at UCB A share price under pressure without good reasons 2022, a transition year Before a very solid recovery starting in 2023. Buy rating reiterated

UCB UCB S.A. (Health Care)

Ucb SA: 1 director

A director at Ucb SA bought 251 shares at 78.408EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members ...

David Vagman ... (+3)
  • David Vagman
  • CFA
  • Maxime Stranart
UCB UCB S.A. (Health Care)

UCB/Preview: Strong 1H21 ahead, 4Q21 trials are key/BUY

We reiterate our BUY on UCB and increase our target price from €120 to €125 following the re-rating of our sample of EU Pharma Midcaps, which are now trading at 21.9x Norm. PER 2021F, vs 14.7x for UCB, despite double-digit core EPS CAGR over 2020-23F and significantly higher R&D investments. Our Embedded Value remains unchanged at €129 per share, as we remain convinced by Bimzelx game changer potential. UCB will report its 1H21 results on 29 July, and we expect strong core EPS growth at +9.7% thanks to the continued growth of blockbusters Cimzia and Vimpat, whilst Evenity's sales growth in the...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Sebastien Malafosse
UCB UCB S.A. (Health Care)

UCB : Bimekizumab on the right track

>Bimekizumab: positive recommendation from CHMP in psoriasis - UCB’s share price gained +3% last Friday (after trading was momentarily suspended) following the positive recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for bimekizumab in the treatment of moderate to severe plaque psoriasis. We are not surprised by this verdict which is more a confirmation of our opinion on its clinical development. To recap, the phase III data (BE SUR...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Sebastien Malafosse
UCB UCB S.A. (Health Care)

UCB : Bimekizumab sur de bons rails

>Bimekizumab : CHMP positif dans le psoriasis - Le cours d’UCB progressait de +3% vendredi dernier (après une suspension momentanée du cours) à la suite d’une recommandation positive du Comité des médicaments à usage humain (CHMP) de l’EMA pour bimekizumab dans le traitement du psoriasis en plaques modéré à sévère. Nous ne voyons pas ce verdict comme une surprise mais plutôt comme la confirmation de notre opinion sur son développement clinique. Pour rappel, les résul...

Jean-Jacques Le Fur
  • Jean-Jacques Le Fur
UCB UCB S.A. (Health Care)

UCB: The right time to look again at UCB | BUY | EUR133(+59%)

UCB - BUY | EUR133(+59%) The right time to look again at UCB A share price under pressure without good reasons 2022, a transition year Before a very solid recovery starting in 2023. Buy rating reiterated

UCB UCB S.A. (Health Care)

Ucb SA: 1 director

A director at Ucb SA bought 251 shares at 78.408EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members ...

David Vagman ... (+3)
  • David Vagman
  • CFA
  • Maxime Stranart
UCB UCB S.A. (Health Care)

UCB/Preview: Strong 1H21 ahead, 4Q21 trials are key/BUY

We reiterate our BUY on UCB and increase our target price from €120 to €125 following the re-rating of our sample of EU Pharma Midcaps, which are now trading at 21.9x Norm. PER 2021F, vs 14.7x for UCB, despite double-digit core EPS CAGR over 2020-23F and significantly higher R&D investments. Our Embedded Value remains unchanged at €129 per share, as we remain convinced by Bimzelx game changer potential. UCB will report its 1H21 results on 29 July, and we expect strong core EPS growth at +9.7% thanks to the continued growth of blockbusters Cimzia and Vimpat, whilst Evenity's sales growth in the...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Sebastien Malafosse
UCB UCB S.A. (Health Care)

UCB : Bimekizumab on the right track

>Bimekizumab: positive recommendation from CHMP in psoriasis - UCB’s share price gained +3% last Friday (after trading was momentarily suspended) following the positive recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for bimekizumab in the treatment of moderate to severe plaque psoriasis. We are not surprised by this verdict which is more a confirmation of our opinion on its clinical development. To recap, the phase III data (BE SUR...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Sebastien Malafosse
UCB UCB S.A. (Health Care)

UCB : Bimekizumab sur de bons rails

>Bimekizumab : CHMP positif dans le psoriasis - Le cours d’UCB progressait de +3% vendredi dernier (après une suspension momentanée du cours) à la suite d’une recommandation positive du Comité des médicaments à usage humain (CHMP) de l’EMA pour bimekizumab dans le traitement du psoriasis en plaques modéré à sévère. Nous ne voyons pas ce verdict comme une surprise mais plutôt comme la confirmation de notre opinion sur son développement clinique. Pour rappel, les résul...

Jean-Jacques Le Fur
  • Jean-Jacques Le Fur
UCB UCB S.A. (Health Care)

UCB: The right time to look again at UCB | BUY | EUR133(+59%)

UCB - BUY | EUR133(+59%) The right time to look again at UCB A share price under pressure without good reasons 2022, a transition year Before a very solid recovery starting in 2023. Buy rating reiterated

UCB UCB S.A. (Health Care)

Ucb SA: 1 director

A director at Ucb SA bought 251 shares at 78.408EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch